Last reviewed · How we verify
BNT327 Equivalent Q3W Dose
BNT327 Equivalent Q3W Dose is a Small molecule drug developed by BioNTech SE. It is currently in Phase 2 development for COVID-19 prevention.
BNT327 is a COVID-19 vaccine candidate that uses a modified mRNA molecule to instruct cells to produce a piece of the SARS-CoQV-2 virus, eliciting an immune response.
BNT327 is a small molecule investigational therapy for breast cancer, specifically studied in conditions such as locally advanced breast cancer, triple negative breast cancer, and metastatic triple negative breast cancers. BNT327 is administered in combination with chemotherapy, including Nab-placlitaxel, as part of a Phase II clinical trial (NCT06449222) to evaluate its safety and preliminary effectiveness.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BNT327 Equivalent Q3W Dose |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by introducing a piece of the SARS-CoV-2 virus's genetic material, called messenger RNA (mRNA), into cells. The cells then use this mRNA to produce a piece of the virus's spike protein, which is recognized by the immune system as foreign and triggers an immune response. This immune response helps to protect against future infections with SARS-CoV-2.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, swelling, or itching at the injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT327 Equivalent Q3W Dose CI brief — competitive landscape report
- BNT327 Equivalent Q3W Dose updates RSS · CI watch RSS
- BioNTech SE portfolio CI
Frequently asked questions about BNT327 Equivalent Q3W Dose
What is BNT327 Equivalent Q3W Dose?
How does BNT327 Equivalent Q3W Dose work?
What is BNT327 Equivalent Q3W Dose used for?
Who makes BNT327 Equivalent Q3W Dose?
What development phase is BNT327 Equivalent Q3W Dose in?
What are the side effects of BNT327 Equivalent Q3W Dose?
Related
- Manufacturer: BioNTech SE — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for COVID-19 prevention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing